• Anti-InfectiveCompleted with Results

  Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis , protocol number Savara SAV005-04

  This study evaluated the effectiveness of the inhaled drug vancomycin hydrochloride inhalation powder (AeroVanc) in adults and children 6 years and older with CF and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).

  • Age:

    6 Years to 21 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30 to 90%

  • Number of Visits:

    13

  • Length of Participation:

    12 months

• Anti-InfectiveCompleted with Results

  AeroVanc for the treatment of MRSA in people with CF , protocol number Savara SAV005-02

  This study evaluated the safety and effectiveness of AeroVanc in treating persistent MRSA lung infections in people with cystic fibrosis.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30 to 100%

  • Number of Visits:

    9

  • Length of Participation:

    16 weeks

• Anti-InfectiveCompleted with Results

  Persistent Methicillin Resistant Staphylococcus Aureus (MRSA) Growth in Respiratory Culture , protocol number DASENB10A0,PMEP11K1, JENNIN16K0, CHMIEL16K0

  This study evaluated the safety and effectiveness of inhaled vancomycin to eliminate the bacterium, methicillin-resistant Staphylococcus aureus (MRSA) in people with CF who have persistent MRSA infection.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    7

  • Length of Participation:

    8 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.